Apollon Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.87M Buy
38,585
+2,918
+8% +$384K 0.06% 270
2026
Q1
$4.97M Sell
35,667
-980
-3% -$137K 0.08% 220
2025
Q4
$4.5M Sell
36,647
-638
-2% -$77.5K 0.08% 219
2025
Q3
$4.14M Buy
37,285
+1,505
+4% +$171K 0.07% 231
2025
Q2
$3.97M Buy
35,780
+871
+2% +$92.7K 0.08% 219
2025
Q1
$3.91M Sell
34,909
-3,090
-8% -$319K 0.09% 211
2024
Q4
$3.51M Buy
37,999
+11,000
+41% +$990K 0.08% 230
2024
Q3
$2.26M Sell
26,999
-276
-1% -$21.1K 0.06% 277
2024
Q2
$1.87M Sell
27,275
-5,711
-17% -$381K 0.06% 310
2024
Q1
$2.42M Sell
32,986
-2,041
-6% -$157K 0.08% 242
2023
Q4
$2.84M Buy
35,027
+18,444
+111% +$1.44M 0.1% 191
2023
Q3
$1.24M Buy
16,583
+218
+1% +$16.8K 0.06% 302
2023
Q2
$1.26M Buy
16,365
+1,097
+7% +$87.5K 0.06% 331
2023
Q1
$1.27M Buy
15,268
+1,954
+15% +$162K 0.08% 268
2022
Q4
$1.14M Buy
13,314
+1,031
+8% +$81.6K 0.08% 264
2022
Q3
$758K Buy
12,283
+1,162
+10% +$73.3K 0.06% 335
2022
Q2
$687K Buy
11,121
+1,446
+15% +$89.5K 0.06% 357
2022
Q1
$575K Sell
9,675
-26,553
-73% -$1.7M 0.04% 426
2021
Q4
$1.18M Buy
36,228
+27,295
+306% +$1.88M 0.09% 246
2021
Q3
$624K Buy
8,933
+4,362
+95% +$306K 0.09% 228
2021
Q2
$315K Buy
4,571
+194
+4% +$13K 0.06% 276
2021
Q1
$283K Buy
+4,377
New +$282K 0.05% 278
2020
Q3
Sell
-2,302
Closed -$177K 355
2020
Q2
$177K Buy
+2,302
New +$176K 0.1% 121

Other funds holding GILD

Apollon Wealth Management's GILD Position: Q2 2026 in Review

Apollon Wealth Management increased its Gilead Sciences (GILD) stake by 8.2% in Q2 2026, buying an estimated $384K and bringing the position to 38,585 shares worth $4.87M. The position accounts for 0.06% of the portfolio, ranked #270.

Apollon Wealth Management first reported a position in GILD in Q2 2020 and has held it in 23 quarters since. The position peaked at $4.97M in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Apollon Wealth Management held 38,585 shares of Gilead Sciences worth $4.87M as of Q2 2026.
  • Apollon Wealth Management bought 2,918 Gilead Sciences shares in Q2 2026, an estimated $384K.
  • Gilead Sciences made up 0.06% of Apollon Wealth Management's portfolio in Q2 2026, its #270 holding.
  • Apollon Wealth Management first reported a position in Gilead Sciences in Q2 2020 and has held it in 23 quarters since.
  • Apollon Wealth Management's Gilead Sciences position peaked at $4.97M in Q1 2026.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.